About: http://data.cimple.eu/news-article/1d25291f1fd2180e04fc9a1827770448cc623c0c3d7a8e150ec4b8eb

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/1d25291f1fd2180e04fc9a1827770448cc623c0c3d7a8e150ec4b8eb Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	European Union regulators fined Israeli drug-maker Teva on Thursday for colluding to delay a cheaper generic version of modafinil, a blockbuster sleep disorder drug. The European Commission said Teva was in breach of EU antitrust rules after it effectively agreed with drug-maker Cephalon, a company it now owns, to keep the cheaper drug off of the market. Teva and Cephalon were fined a combined 60.5 million euros ($72 million), but the company can appeal this through the European courts. The EU launched the case in 2011 and pressed charges in July 2017. Under the alleged agreement, Teva committed not to market a cheaper generic version of modafinil, Cephalon's drug for sleep disorders, the EU said. EU Competition Commissioner Margrethe Vestager said Teva's "pay-for-delay" agreement "harmed patients and national health systems, depriving them of more affordable medicines." In a similar case, in 2014 the commission hit French drugs giant Servier with a 331-million-euro fine for colluding to delay a cheaper generic version of perindopril, a popular blood pressure treatment. Teva was also fined in that case. Generic products are far cheaper than brand medicines and lead to huge savings to patients and health care providers while remaining just as effective. But in so-called pay-for-delay deals, drug makers secretly compensate generic rivals to thwart the introduction of cheaper versions of blockbuster drugs for an agreed time. Drug makers argue that the arrangement allows them sufficient time to recoup expensive research and marketing costs incurred to bring their products to the market. Teva settled similar litigation with US anti-trust authorities in 2015. arp/dc/bmm
schema:headline	EU fines Teva over delaying cheap sleep disorder drug
schema:mentions	Teva Pharmaceutical Industries Hypertension European Commission European Union France United States Perindopril Modafinil Cephalon Laboratoires Servier European Commissioner for Competition Sleep disorder ARP Instruments Margrethe Vestager Competition law
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-11-26 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	76 (xsd:integer)
http://data.cimple...tology#hasEmotion	anger

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software